Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Lineage Cell Therapeutics, Inc. (BTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2023 December 31, 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 33,886 $ 11,355 Marketable securities 12,039 46,520 Accounts receivable, net 443 297 Prepaid expenses and other current assets 2,123 1,828 Total current assets 48,491 60,000 NONCURRENT ASSETS Property and equipment, net 5,310 5,673 Deposits and other long-term assets 588 627 Goodwill 10,672 10,672 Intangible assets, net 46,627 46,692 TOTAL ASSETS $ 111,688 $ 123,664 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 4,685 $ 8,608 Lease liabilities, current portion 933 916 Financing lease, current portion 54 36 Deferred revenues 10,379 9,421 Other current liabilities 1 - Total..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2023 December 31, 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $ 15,451 $ 11,355 Marketable securities 31,363 46,520 Accounts receivable, net 203 297 Prepaid expenses and other current assets 2,638 1,828 Total current assets 49,655 60,000 NONCURRENT ASSETS Property and equipment, net 5,584 5,673 Deposits and other long-term assets 635 627 Goodwill 10,672 10,672 Intangible assets, net 46,659 46,692 TOTAL ASSETS $ 113,205 $ 123,664 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 5,252 $ 8,608 Lease liabilities, current portion 912 916 Financing lease, current portion 51 36 Deferred revenues 11,009 9,421 Other current liabilities 1 - Tota..." |
|
| 03/09/2023 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31, 2022 December 31, 2021 ASSETS CURRENT ASSETS Cash and cash equivalents $ 11,355 $ 55,742 Marketable securities 46,520 2,616 Accounts and grants receivable, net 297 50,840 Prepaid expenses and other current assets 1,828 2,351 Total current assets 60,000 111,549 NONCURRENT ASSETS Property and equipment, net 5,673 4,872 Deposits and other long-term assets 627 630 Goodwill 10,672 10,672 Intangible assets, net 46,692 46,822 TOTAL ASSETS $ 123,664 $ 174,545 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 8,608 $ 27,969 Lease liabilities, current portion 916 801 Financing lease, current portion 36 30 Deferred revenues 9,421 18,119 Liability classified warra..." |
|
| 11/10/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/10/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2021 December 31, 2020 ASSETS CURRENT ASSETS Cash and cash equivalents $ 60,809 $ 32,585 Marketable equity securities 4,295 8,977 Trade accounts receivable, net 79 4 Prepaid expenses and other current assets 3,161 2,433 Total current assets 68,344 43,999 NONCURRENT ASSETS Property and equipment, net 4,728 5,630 Deposits and other long-term assets 614 616 Goodwill 10,672 10,672 Intangible assets, net 46,854 47,032 TOTAL ASSETS $ 131,212 $ 107,949 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 6,705 $ 6,813 Lease liabilities, current portion 801 746 Financing lease, current portion 17 16 Deferred revenues 975 193 Liability classified warran..." |
|
| 08/12/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 11/04/2020 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2019 ASSETS CURRENT ASSETS Cash and cash equivalents $ 32,565 $ 9,497 Marketable equity securities 5,481 21,219 Promissory note from Juvenescence - 23,616 Trade accounts and grants receivable, net 276 317 Receivables from affiliates, net - 7 Prepaid expenses and other current assets 1,414 2,863 Total current assets 39,736 57,519 NONCURRENT ASSETS Property and equipment, net 4,849 8,175 Deposits and other long-term assets 666 864 Goodwill 10,672 10,672 Intangible assets, net 47,167 48,248 TOTAL ASSETS $ 103,090 $ 125,478 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 7,214 $ 5,226 Financing lease and right of use lease liabilities, current..." |
|
| 08/06/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results|
Docs:
|
"LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2020 December 31, 2019 ASSETS CURRENT ASSETS Cash and cash equivalents $ 9,832 $ 9,497 Marketable equity securities 15,933 21,219 Promissory note from Juvenescence 23,994 23,616 Trade accounts and grants receivable, net 253 317 Receivables from affiliates, net 47 7 Prepaid expenses and other current assets 2,225 2,863 Total current assets 52,284 57,519 NONCURRENT ASSETS Property and equipment, net 7,539 8,175 Deposits and other long-term assets 637 864 Goodwill 10,672 10,672 Intangible assets, net 47,750 48,248 TOTAL ASSETS $ 118,882 $ 125,478 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 5,321 $ 5,226 Financing lease and right of use lease ..." |
|
| 03/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results|
Docs:
|
"BIOTIME, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2019 December 31, 2018 ASSETS CURRENT ASSETS Cash and cash equivalents $ 8,210 $ 23,587 Marketable equity securities 8,477 7,154 Trade accounts and grants receivable, net 1,671 767 Receivables from affiliates, net - 2,112 Prepaid expenses and other current assets 2,101 2,738 Total current assets 20,459 36,358 NONCURRENT ASSETS Property and equipment, net 8,720 5,835 Deposits and other long-term assets 815 505 Promissory note from Juvenescence 22,860 22,104 Equity method investment in OncoCyte, at fair value 36,539 20,250 Equity method investment in Asterias, at fair value - 13,483 Goodwill 12,977 - Intangible assets, net 49,321 3,125 TOTAL ASSETS $ 151,691 $ 101,660 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LI..." |
|
| 05/09/2019 |
8-K
| Quarterly results|
Docs:
|
"BIOTIME, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2019 December 31, 2018 ASSETS CURRENT ASSETS Cash and cash equivalents $ 18,011 $ 23,587 Marketable equity securities 9,085 7,154 Trade accounts and grants receivable, net 1,402 767 Receivables from affiliates, net - 2,112 Prepaid expenses and other current assets 2,158 2,738 Total current assets 30,656 36,358 NONCURRENT ASSETS Property and equipment, net 8,918 5,835 Deposits and other long-term assets 890 505 Promissory note from Juvenescence 22,482 22,104 Equity method investment in OncoCyte, at fair value 57,963 20,250 Equity method investment in Asterias, at fair value - 13,483 Goodwill 12,977 - Intangible assets, net 49,829 3,125 TOTAL ASSETS $ 183,715 $ 101,660 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT ..." |
|
| 03/14/2019 |
8-K
| Quarterly results|
Docs:
|
"BIOTIME, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS CURRENT ASSETS Cash and cash equivalents $ 23,587 $ 36,838 Marketable equity securities 7,154 1,337 Trade accounts and grants receivable, net 767 780 Landlord receivable 840 - Receivables from affiliates, net 2,112 2,266 Prepaid expenses and other current assets 1,898 1,402 Total current assets 36,358 42,623 NONCURRENT ASSETS Property and equipment, net 5,835 5,533 Deposits and other long term assets 505 1,018 Promissory note from Juvenescence 22,104 - Equity method investment in OncoCyte, at fair value 20,250 68,235 Equity method investment in Asterias, at fair value 13,483 48,932 Intangible assets, net 3,125 6,900 TOTAL ASSETS $ 101,660 $ 173,241 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts p..." |
|
| 11/08/2018 |
8-K
| Quarterly results|
Docs:
|
"BIOTIME, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2018 ASSETS CURRENT ASSETS Cash and cash equivalents $ 19,467 $ 36,838 Marketable equity securities 1,972 1,337 Trade accounts and other receivables, net 721 780 Receivable from affiliates, net 2,185 2,266 Receivable from Juvenescence 10,800 - Prepaid expenses and other current assets 1,761 1,402 Total current assets 36,906 42,623 NONCURRENT ASSETS Property, plant and equipment, net 5,117 5,533 Deposits and other long-term assets 518 1,018 Promissory note from Juvenescence 21,730 - Equity method investment in AgeX, at fair value 43,248 - Equity method investment in OncoCyte, at fair value 36,686 68,235 Equity method investment in Asterias, at fair value 28,272 48,932 Intangible assets, net 3,600 6,900 TOTAL ..." |
|
| 08/02/2018 |
8-K
| Quarterly results |
| 05/10/2018 |
8-K
| Quarterly results |
| 03/15/2018 |
8-K
| Quarterly results |
| 11/09/2017 |
8-K
| Quarterly results |
| 08/02/2017 |
8-K
| Quarterly results |
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 11/03/2016 |
8-K
| Quarterly results |
| 08/09/2016 |
8-K
| Form 8-K - Current report |
| 05/10/2016 |
8-K
| Form 8-K - Current report |
| 11/09/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 05/11/2015 |
8-K
| Quarterly results |
| 03/11/2015 |
8-K
| Quarterly results |
| 11/10/2014 |
8-K
| Quarterly results |
|
|
|